What is the risk of hyperkalaemia in heart failure?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 15, 2011, Pages 2329-2338

  Bielecka Dabrowa, Agata ^a   Rysz, Jacek ^a   Mikhailidis, Dimitri P ^b   Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diuretics; Heart failure; Hyperkalemia; Potassium

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; ALISKIREN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; POTASSIUM; RENIN; SODIUM; SPIRONOLACTONE;

ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETIC PATIENT; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPOALDOSTERONISM; HYPOTENSION; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MEMBRANE STEADY POTENTIAL; OXIDATIVE STRESS; PATIENT SAFETY; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM TRANSPORT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESUSCITATION; REVIEW; SUDDEN DEATH; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

HEART FAILURE; HOMEOSTASIS; HUMANS; HYPERKALEMIA; POPULATION GROUPS; POTASSIUM; POTASSIUM CHANNELS; RISK FACTORS; SODIUM CHANNEL BLOCKERS; SPIRONOLACTONE;

EID: 80052880100     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.601743     Document Type: Review

References (62)

1. Gibbs LM, Addington-Hall J, Gibbs JS. Dying from 1. heart failure: lessons from palliative care. Many patients would benefit from palliative care at the end of their lives. BMJ 1998;317:961-2
2. Stewart S, MacIntyre K, Hole DJ, et al. More "malignant" than cancer? Five-year survival following first admission for heart failure. Eur J Heart Fail 2001;3:315-22 (Pubitemid 32895839)
3. Croft JB, Giles WH, Pollard RA, et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505-10 (Pubitemid 29108917)
4. Murdoch DR, Love MO, Robb SD, et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979. Eur Heart J 1998;19:1829-35 (Pubitemid 28556653)
5. Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159:29-34 (Pubitemid 29044116)
6. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993;88:2953-61 (Pubitemid 23360223)
7. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-83 (Pubitemid 29243156)
8. Dursun I, Sahin M. Difficulties in maintaining potassium homeostasis in patients with heart failure. Clin Cardiol 2006;29:388-92 (Pubitemid 44353325)
9. Martin HE, Wertman M, Westover L, et al. Clinical potassium problems. Calif Med 1950;72:133-41
10. Weiss J. Ion channels in cardiac muscle. The myocardium. 2nd edition. Academic Press, San Diego, CA, USA, 1997
11. Rau EE, Shine KI, Langer GA. Potassium exchange and mechanical performance in anoxic mammalian myocardium. Am J Physiol 1997;232:H85-94
12. Weiss J, Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest 1985;75:436-47 (Pubitemid 15143483)
13. Aslam S, Friedman EA, Ifudu O. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in haemodialysis patients. Nephrol Dial Transplant 2002;17:1639-42 (Pubitemid 35012167)
14. Wilde AAM, Kleber AG. The combined effects of hypoxia, high K+, and acidosis on the intracellular sodium activity and resting potential in guinea pig papillary muscle. Circ Res 1986;58:249-56 (Pubitemid 16107749)
15. Wilde AA, Aksnes G. Myocardial potassium loss and cell depolarisation in ischaemia and hypoxia. Cardiovasc Res 1995;29:1-15
16. Goldhaber J. Metabolism in normal and ischemic myocardium. The Myocardium. 2nd edition. Academic Press, San Diego, CA, USA, 1997
17. Suh A, DeJesus E, Rosner K, et al. Racial differences in potassium disposal. Kidney Int 2004;66:1076-81 (Pubitemid 39121012)
18. Cavallari LH, Groo VL, Momary KM, et al. Racial differences in potassium response to spironolactone in heart failure. Congest Heart Fail 2006;12:200-5
19. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin aldosterone system. N Engl J Med 2004;351: 585-92
20. Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:3A-11A (Pubitemid 23046405)
21. Shah KB, Rao K, Sawyer R, et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845-9 (Pubitemid 41224809)
22. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000;109:307-14
23. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211-14 (Pubitemid 36092186)
24. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303 (Pubitemid 39092680)
25. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148:971-8 (Pubitemid 39646969)
26. Ramadan FH, Masoodi N, El Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther 2005;30:233-9 (Pubitemid 41603046)
27. Saito M, Takada M, Hirooka K, et al. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther 2005;30:603-10 (Pubitemid 43960988)
28. Poggio R, Grancelli HO, Miriuka SG. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Postgrad Med J 2010;86:136-42
29. Parham WA, Mehdirad AA, Biermann KM, et al. Hyperkalemia revisited. Tex Heart Inst J 2006;33:40-7
30. Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003;327:147-9 (Pubitemid 36876210)
31. Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41
32. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8
33. Ahmed MI, Ekundayo OJ, Mujib M, et al. Mild hyperkalemia and outcomes in chronic heart failure: A propensity matched study. Int J Cardiol 2010;144:383-8
34. Desai A. Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system balancing risk and benefit. Circulation 2008;118:1609-11
35. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016
36. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97 (Pubitemid 33126826)
37. Pitt B, Bakris G, Ruilope LM, et al. on Behalf of the EPHESUS Investigators. Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118:1643-50
38. Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007;13:170-7 (Pubitemid 46591953)
39. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;36:11-21
40. The Randomized Aldactone Evaluation Study (RALES). Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996;78:902-7
41. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-19 (Pubitemid 37098553)
42. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17 (Pubitemid 29407370)
43. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51 (Pubitemid 39025171)
44. The task force on acute heart failure of the European Society of Cardiology. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J 2005;26:384-416
45. Lima MV, Ochiai ME, Cardoso JN, et al. Hyperkalemia during spironolactone use in patients with decompensated heart failure. Arq Bras Cardiol 2008;91:177-82
46. Cavallari LH, Groo VL, Viana MA, et al. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy 2010;30:1-9
47. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89
48. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21 (Pubitemid 36384098)
49. Schoolwerth AC, Sica DA, Ballermann BJ, et al. Council on the kidney in cardiovascular disease and the council for high blood pressure research of the American Heart Association. Renal considerations in angiotensin-converting enzyme inhibitor therapy: a statement for healthcare professionals from the council on the kidney in cardiovascular disease and the council for high blood pressure research of the American Heart Association. Circulation 2001;104:1985-91 (Pubitemid 32983246)
50. Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008;9:509-15 (Pubitemid 351425379)
51. Desai AS, Swedberg K, McMurray JJV, et al. on behalf of the CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol 2007;50:1959-66 (Pubitemid 350046342)
52. Krum H, Maggioni A. Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. Clin Cardiol 2010;33:536-41
53. Pitt B, Latini R, Maggioni AP, et al. Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail 2011; [Epub ahead of print]
54. Solomon SD, Hee Shin S, Shah A, et al. for the Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 2011;32(10):1227-34
55. Krum H, Massie B, Abraham WT, et al. ATMOSPHERE investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren trial to minimize outcomes in patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13(1):107-14
56. Martin FL, Stevens TL, Cataliotti A, et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 2005;67:1723-30 (Pubitemid 40577706)
57. Cuculi F, Erne P. Combined neutral endopeptidase inhibitors. Expert Opin Investig Drugs 2011;20:457-63
58. Jacob MS, Tang WH. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr Heart Fail Rep 2011;8(1):7-13
59. Mujib M, Desai R, Levitan EB, et al. Prospective population studies of incident heart failure without data on baseline left ventricular ejection fraction. Arch Med Sci 2010;6(5):686-8
60. Bielecka-Dabrowa A, Mikhailidis DP, Jones L, et al. The meaning of hypokalemia in heart failure. Int J Cardiol 2011; In press. doi: 10.1016/j.ijcard.2011.06.121
61. Dickstein K, Cohen-Solal A, Filippatos E, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442 . The current guidelines for the diagnosis and treatment of chronic heart failure.
62. Lubas A, Zelichowski G, Prochnicka A, et al. Renal vascular response to angiotensin II inhibition in intensive antihypertensive treatment of essential hypertension. Arch Med Sci 2010;6(4):533-538